Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wendy Stock

Showing results (11-20 of 322) with videos related to

Pageof 33
Sort By:
Blood|February 24, 2019
Taking a "BiTE out of ALL": blinatumomab approval for MRD-positive ALLEmily Curran, Wendy Stock
Blood|March 3, 2018
"Dar"-ing to target CD38 in T-ALLJoseph Wynne, Wendy Stock
Current Opinion in Hematology|June 10, 2008
Progress in the treatment of adults with acute lymphoblastic leukemiaSarah Larson, Wendy Stock
Leukemia & Lymphoma|May 7, 2015
Is it time to use minimal residual disease to stratify post-remission treatment for acute myeloid leukemia?Hongtao Liu, Wendy Stock
Journal of Adolescent and Young Adult Oncology|January 27, 2016
Intergroup Trial C10403: A Pediatric Treatment Approach to Improve Outcomes in Adolescents and Young Adults with Acute Lymphoblastic LeukemiaKatherine Breitenbach, Wendy Stock
Hematology/Oncology Clinics of North America|October 15, 2009
Preface: acute lymphoblastic leukemia--quo vadis?Meir Wetzler, Wendy Stock
Blood|March 26, 2015
How I treat acute lymphoblastic leukemia in older adolescents and young adultsEmily Curran, Wendy Stock
Hematology. American Society of Hematology. Education Program|December 10, 2017
Progress in adult ALL: incorporation of new agents to frontline treatmentJessica Leonard, Wendy Stock
Current Hematologic Malignancy Reports|April 29, 2010
Approaches to treatment for acute lymphoblastic leukemia in adolescents and young adultsRyan Mattison, Wendy Stock
Oncology (Williston Park, N.Y.)|March 17, 2017
Counterpoint: Standard vs Investigational Agents as Upfront Treatment for High-Risk AMLAndrew M Brunner, Wendy Stock
Pageof 33

Showing results (11-20 of 322) with videos related to

Sort By:
Pageof 33
Blood|February 24, 2019
Taking a "BiTE out of ALL": blinatumomab approval for MRD-positive ALLEmily Curran, Wendy Stock
Blood|March 3, 2018
"Dar"-ing to target CD38 in T-ALLJoseph Wynne, Wendy Stock
Current Opinion in Hematology|June 10, 2008
Progress in the treatment of adults with acute lymphoblastic leukemiaSarah Larson, Wendy Stock
Leukemia & Lymphoma|May 7, 2015
Is it time to use minimal residual disease to stratify post-remission treatment for acute myeloid leukemia?Hongtao Liu, Wendy Stock
Journal of Adolescent and Young Adult Oncology|January 27, 2016
Intergroup Trial C10403: A Pediatric Treatment Approach to Improve Outcomes in Adolescents and Young Adults with Acute Lymphoblastic LeukemiaKatherine Breitenbach, Wendy Stock
Hematology/Oncology Clinics of North America|October 15, 2009
Preface: acute lymphoblastic leukemia--quo vadis?Meir Wetzler, Wendy Stock
Blood|March 26, 2015
How I treat acute lymphoblastic leukemia in older adolescents and young adultsEmily Curran, Wendy Stock
Hematology. American Society of Hematology. Education Program|December 10, 2017
Progress in adult ALL: incorporation of new agents to frontline treatmentJessica Leonard, Wendy Stock
Current Hematologic Malignancy Reports|April 29, 2010
Approaches to treatment for acute lymphoblastic leukemia in adolescents and young adultsRyan Mattison, Wendy Stock
Oncology (Williston Park, N.Y.)|March 17, 2017
Counterpoint: Standard vs Investigational Agents as Upfront Treatment for High-Risk AMLAndrew M Brunner, Wendy Stock
Pageof 33